Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer

Oncology Research

Volumn 18, Issue 9, 2010, Pages 437-444

  Zhuang, Luhong ^a   Bai, Jianling ^a   Huang, Huaying ^a   Tang, Cuiju ^a   Yang, Jinsong ^a   Zhou, Baoning ^a   Gong, Yongling ^a   Duanmu, Zhong ^a   Chen, Jinfei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Colorectal cancer; Irinotecan; Meta analysis; Oxaliplatin; Systematic review

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; MEDICAL LITERATURE; META ANALYSIS; METASTASIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; OVERALL SURVIVAL; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SKIN DISEASE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

EID: 77952353767     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504010X12671222663511     Document Type: Article

References (33)

1. Jemal, A.; Thomas, A.; Murray, T.; Thun, M. Cancer statistics. CA. Cancer J. Clin. 52:23-47; 2002.
2. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol. 10:896-903; 1992.
3. Kohne, C. H.; Schoffski, P.; Wilke, H.; Käufer, C.; Andreesen, R.; Ohl, U.; Klaasen, U.; Westerhausen, M.; Hiddemann, W.; Schott, G.; Harstick, A.; Bade, J.; Horster, A.; Schubert, U.; Hecker, H.; Dörken, B.; Schmoll, H. J. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer. J. Clin. Oncol. 16:418-426; 1998.
4. Douillard, J. Y.; Cunningham, D.; Roth, A. D.; Navarro, M.; James, R. D.; Karasek, P.; Jandik, P.; Iveson, T.; Carmichael, J.; Alakl, M.; Gruia, G.; Awad, L.; Rougier, P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047; 2000.
5. Saltz, L. B.; Cox, J. V.; Blanke, C.; Rosen, L. S.; Fehrenbacher, L.; Moore, M. J.; Maroun, J. A.; Ackland, S. P.; Locker, P. K.; Pirotta, N.; Elfring, G. L.; Miller, L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343:905-914; 2000.
6. Giacchetti, S.; Perpoint, B.; Zidani, R.; Le Bail, N.; Faggiuolo, R.; Focan, C.; Chollet, P.; Llory, J. F.; Letourneau, Y.; Coudert, B.; Bertheaut-Cvitkovic, F.; Larregain-Fournier, D.; Le Rol, A.; Walter, S.; Adam, R.; Misset, J. L.; Lévi, F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18:136-147; 2000.
7. de Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; Cassidy, J.; Boni, C.; Cortes-Funes, H.; Cervantes, A.; Freyer, G.; Papamichael, D.; Le Bail, N.; Louvet, C.; Hendler, D.; de Braud, F.; Wilson, C.; Morvan, F.; Bonetti, A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18:2938-2947; 2000.
8. Hsiang, Y. H.; Hertzberg, R.; Hecht, S.; Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260:14873-14878; 1985.
9. Rougier, P.; Van Cutsem, E.; Bajetta, E.; Niederle, N.; Possinger, K.; Labianca, R.; Navarro, M.; Morant, R.; Bleiberg, H.; Wils, J.; Awad, L.; Herait, P.; Jacques, C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412; 1998.
10. Saltz, L. B.; Cox, J. V.; Blanke, C.; Rosen, L. S.; Fehrenbacher, L.; Moore, M. J.; Maroun, J. A.; Ackland, S. P.; Locker, P. K.; Pirotta, N.; Elfring, G. L.; Miller, L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 343:905-914; 2000.
11. Raymond, E.; Faivre, S.; Woynarowski, J. M.; Chaney, S. G. Oxaliplatin: Mechanism of action and antineoplastic activity. Semin. Oncol. 25:4-12; 1998.
12. Woynarowski, J. M.; Chapman, W. G.; Napier, C.; Herzig, M. C.; Juniewicz, Pn. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol. Pharmacol. 54:770-777; 1998.
13. Raymond, E.; Chaney, S. G.; Taamma, A.; Cvitkovic, E. Oxaliplatin: A review of preclinical and clinical studies. Ann. Oncol. 9:1053-1071; 1998.
14. Becouarn, Y.; Ychou, M.; Ducreux, M.; Borel, C.; Bertheault-Cvitkovic, F.; Seitz, J. F.; Nasca, S.; Nguyen, T. D.; Paillot, B.; Raoul, J. L.; Duffour, J.; Fandi, A.; Dupont-André, G.; Rougier, P. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J. Clin. Oncol. 16:2739-2744; 1998.
15. Díaz-Rubio, E.; Sastre, J.; Zaniboni, A.; Labianca, R.; Cortés-Funes, H.; de Braud, F.; Boni, C.; Benavides, M.; Dallavalle, G.; Homerin, M. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multi-centric study. Ann. Oncol. 9:105-108; 1998.
16. Machover, D.; Diaz-Rubio, E.; de Gramont, A.; Schilf, A.; Gastiaburu, J. J.; Brienza, S.; Itzhaki, M.; Metzger, G.; N'Daw, D.; Vignoud, J.; Abad, A.; Francois, E.; Gamelin, E.; Marty, M.; Sastre, J.; Seitz, J. F.; Ychou, M. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 7:95-99; 1996.
17. Fischel, J. L.; Etienne, M. C.; Formento, P.; Milano, G. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: Preclinical data. Clin. Cancer. Res. 4:2529-2535; 1998.
18. de Gramont, A.; Vignoud, J.; Tournigand, C.; Louvet, C.; André, T.; Varette, C.; Raymond, E.; Moreau, S.; Le Bail, N.; Krulik, M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer 33:214-219; 1997.
19. Janinis, J.; Papakostas, P.; Samelis, G.; Skarlos, D.; Papagianopoulos, P.; Fountzilas, G. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: A Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. Ann. Oncol. 11:163-167; 2000.
20. André, T.; Louvet, C.; Maindrault-Goebel, F.; Couteau, C.; Mabro, M.; Lotz, J. P.; Gilles-Amar, V.; Krulik, M.; Carola, E.; Izrael, V.; de Gramont, A. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur. J. Cancer 35:1343-1347; 1999.
21. Punt, C. J. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann. Oncol. 15:1453-1459; 2004.
22. Cunningham, D.; Pyrhönen, S.; James, R. D.; Punt, C. J.; Hickish, T. F.; Heikkila, R.; Johannesen, T. B.; Starkhammar, H.; Topham, C. A.; Awad, L.; Jacques, C.; Herait, P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418; 1998.
23. Becouarn, Y.; Rougier, P. Clinical efficacy of oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer. Semin. Oncol. 25:23-31; 1998.
24. Parmar, M. K.; Torri, V.; Stewart, L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med. 17:2815-2534; 1998.
25. Laird, N. M.; Mosteller, F. Some statistical methods for combining experimental results. Int. J. Technol. Assess. Health Care 6:5-30; 1990.
26. Delaunoit, T.; Goldberg, R. M.; Sargent, D. J.; Morton, R. F.; Fuchs, C. S.; Findlay, B. P.; Thomas, S. P.; Salim, M.; Schaefer, P. L.; Stella, P. J.; Green, E.; Mailliard, J. A. Mortality associated with daily bolus 5-fluorouracil/ leucovorin administered in combination with either irinotecan or oxaliplatin: Results from Intergroup Trial N9741. Cancer 101:2170-2176; 2004.
27. Goldberg, R. M.; Sargent, D. J.; Morton, R. F.; Fuchs, C. S.; Ramanathan, R. K.; Williamson, S. K.; Findlay, B. P.; Pitot, H. C.; Alberts, S. R. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22:23-30; 2003.
28. Goldberg, R. M.; Sargent, D. J.; Morton, R. F.; Fuchs, C. S.; Ramanathan, R. K.; Williamson, S. K.; Findlay, B. P.; Pitot, H. C.; Alberts, S. R. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J. Clin. Oncol. 24:3347-3353; 2006.
29. Colucci, G.; Gebbia, V.; Paoletti, G.; Giuliani, F.; Caruso, M.; Gebbia, N.; Carteni, G.; Agostara, B.; Pezzella, G.; Manzione, L.; Borsellino, N.; Misino, A.; Romito, S.; Durini, E.; Cordio, S.; Seri, M. D.; Lopez, M.; Maiello, E. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J. Clin. Oncol. 23:4866-4875; 2005.
30. Kalofonos, H. P.; Aravantinos, G.; Kosmidis, P.; Papakostas, P.; Economopoulos, T.; Dimopoulos, M.; Skarlos, D.; Bamias, A.; Pectasides, D.; Chalkidou, S.; Karina, M.; Koutras, A.; Samantas, E.; Bacoyiannis, C.; Samelis, G. F.; Basdanis, G.; Kalfarentzos, F.; Fountzilas, G. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: A multicenter, randomized, phase II study. Ann. Oncol. 16: 869-877; 2005.
31. Tournigand, C.; André, T.; Achille, E.; Lledo, G.; Flesh, M.; Mery-Mignard, D.; Quinaux, E.; Couteau, C.; Buyse, M.; Ganem, G.; Landi, B.; Colin, P.; Louvet, C.; de Gramont, A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J. Clin. Oncol. 22:229-237; 2004.
32. Comella, P.; Massidda, B.; Filippelli, G.; Palmeri, S.; Natale, D.; Farris, A.; De Vita, F.; Buzzi, F.; Tafuto, S.; Maiorino, L.; Mancarella, S.; Leo, S.; Lorusso, V.; De Lucia, L.; Roselli, M. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase III trial. Ann. Oncol. 16:878-886; 2005.
33. Yoshino, T.; Boku, N.; Onozawa, Y.; Hironaka, S.; Fukutomi, A.; Yamaguchi, Y.; Hasuike, N.; Yamazaki, K.; Machida, N.; Ono, H. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: Experience in a single institution in Japan. Jpn. J. Clin. Oncol. 37:686-691; 2007.